Alejandra Graciela Palma1, Mileni Soares Machado1, María Cecilia Lira1, Francisco Rosa1, María Fernanda Rubio1,2, Gabriela Marino2,3, Basilio Aristidis Kotsias2,3, Mónica Alejandra Costas4,5. 1. Laboratorio de Biología Molecular y Apoptosis, Instituto de Investigaciones Médicas Alfredo Lanari, IDIM-UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Combatientes de Malvinas 3150. Cuerpo II, Piso 1, C1427ARO, Buenos Aires, Argentina. 2. CONICET, Buenos Aires, Argentina. 3. Laboratorio de Canales Iónicos, Instituto de Investigaciones Médicas Alfredo Lanari, IDIM-UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Combatientes de Malvinas 3150, C1427ARO, Buenos Aires, Argentina. 4. Laboratorio de Biología Molecular y Apoptosis, Instituto de Investigaciones Médicas Alfredo Lanari, IDIM-UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Combatientes de Malvinas 3150. Cuerpo II, Piso 1, C1427ARO, Buenos Aires, Argentina. mcostasra@hotmail.com. 5. CONICET, Buenos Aires, Argentina. mcostasra@hotmail.com.
Abstract
PURPOSE: CFTR mutations not only cause cystic fibrosis, but also increase the risk of colorectal cancer. A putative role of CFTR in colorectal cancer patients without cystic fibrosis has so far, however, not been investigated. RAC3 is a nuclear receptor coactivator that has been found to be overexpressed in several human tumors, and to be required for maintaining cancer stemness. Here, we investigated the functional relationship between CFTR and RAC3 for maintaining cancer stemness in human colorectal cancer. METHODS: Cancer stemness was investigated by analysing the expression of stem cell markers, clonogenic growth and selective retention of fluorochrome, using stable transfection of shCFTR or shRAC3 in HCT116 colorectal cancer cells. In addition, we performed pathway enrichment and network analyses in both primary human colorectal cancer samples (TCGA, Xena platform) and Caco-2 colorectal cancer cells including (1) CD133+ or CD133- side populations and (2) CFTRwt or CFTRmut cells (ConsensusPathDB, STRING, Cytoscape, GeneMANIA). RESULTS: We found that the CD133+ side population expresses higher levels of RAC3 and CFTR than the CD133- side population. RAC3 overexpression increased CFTR expression, whereas CFTR downregulation inhibited the cancer stem phenotype. CFTR mRNA levels were found to be increased in colorectal cancer samples from patients without cystic fibrosis compared to those with CFTR mutations, and this correlated with an increased expression of RAC3. The expression pattern of a gene set involved in inflammatory response and nuclear receptor modulation in CD133+ Caco-2 cells was found to be shared with that in CFTRwt Caco-2 cells. These genes may contribute to colorectal cancer development. CONCLUSIONS: CFTR may play a non-tumor suppressor role in colorectal cancer development and maintenance involving enhancement of the expression of a set of genes related to cancer stemness and development in patients without CFTR mutations.
PURPOSE: CFTR mutations not only cause cystic fibrosis, but also increase the risk of colorectal cancer. A putative role of CFTR in colorectal cancer patients without cystic fibrosis has so far, however, not been investigated. RAC3 is a nuclear receptor coactivator that has been found to be overexpressed in several human tumors, and to be required for maintaining cancer stemness. Here, we investigated the functional relationship between CFTR and RAC3 for maintaining cancer stemness in human colorectal cancer. METHODS: Cancer stemness was investigated by analysing the expression of stem cell markers, clonogenic growth and selective retention of fluorochrome, using stable transfection of shCFTR or shRAC3 in HCT116 colorectal cancer cells. In addition, we performed pathway enrichment and network analyses in both primary human colorectal cancer samples (TCGA, Xena platform) and Caco-2 colorectal cancer cells including (1) CD133+ or CD133- side populations and (2) CFTRwt or CFTRmut cells (ConsensusPathDB, STRING, Cytoscape, GeneMANIA). RESULTS: We found that the CD133+ side population expresses higher levels of RAC3 and CFTR than the CD133- side population. RAC3 overexpression increased CFTR expression, whereas CFTR downregulation inhibited the cancer stem phenotype. CFTR mRNA levels were found to be increased in colorectal cancer samples from patients without cystic fibrosis compared to those with CFTR mutations, and this correlated with an increased expression of RAC3. The expression pattern of a gene set involved in inflammatory response and nuclear receptor modulation in CD133+ Caco-2 cells was found to be shared with that in CFTRwt Caco-2 cells. These genes may contribute to colorectal cancer development. CONCLUSIONS: CFTR may play a non-tumor suppressor role in colorectal cancer development and maintenance involving enhancement of the expression of a set of genes related to cancer stemness and development in patients without CFTR mutations.
Entities:
Keywords:
CD133; CFTR; Cancer stem cells; Colorectal cancer; RAC3
Authors: B L N Than; J F Linnekamp; T K Starr; D A Largaespada; A Rod; Y Zhang; V Bruner; J Abrahante; A Schumann; T Luczak; A Niemczyk; M G O'Sullivan; J P Medema; R J A Fijneman; G A Meijer; E Van den Broek; C A Hodges; P M Scott; L Vermeulen; R T Cormier Journal: Oncogene Date: 2016-01-11 Impact factor: 9.867
Authors: Laura C Panelo; Mileni Soares Machado; María F Rubio; Felipe Jaworski; Cecilia V Alvarado; Leonardo A Paz; Alejandro J Urtreger; Elba Vazquez; Mónica A Costas Journal: Oncotarget Date: 2017-12-22
Authors: Ashlee M Strubberg; Jinghua Liu; Nancy M Walker; Casey D Stefanski; R John MacLeod; Scott T Magness; Lane L Clarke Journal: Cell Mol Gastroenterol Hepatol Date: 2017-12-07
Authors: Mileni Soares Machado; Francisco D Rosa; María C Lira; Alejandro J Urtreger; María F Rubio; Mónica A Costas Journal: EXCLI J Date: 2018-11-02 Impact factor: 4.068
Authors: Cecilia Viviana Alvarado; María Fernanda Rubio; Pablo Nicolas Fernández Larrosa; Laura Carolina Panelo; Pablo Javier Azurmendi; Marina Ruiz Grecco; Giselle Astrid Martínez-Nöel; Mónica Alejandra Costas Journal: FEBS Open Bio Date: 2014-05-02 Impact factor: 2.693
Authors: María Fernanda Rubio; María Cecilia Lira; Francisco Damián Rosa; Adrían Dario Sambresqui; María Cecilia Salazar Güemes; Mónica Alejandra Costas Journal: Cancer Cell Int Date: 2017-11-28 Impact factor: 5.722